AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic dermatitis treatment, ANB032, after the drug failed ... Read More
GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab) to include all adult patients with primary ... Read More
GSK secures full Jemperli FDA approval for endometrial cancer treatment
Biopharma company GSK has secured the full approval of the US Food and Drug Administration (FDA) for its Jemperli (dostarlimab-gxly) drug for recurrent or advanced ... Read More